Advertisement

Parkinsonian Drugs: Indications

  • Wolfgang H. JostEmail author
Living reference work entry
  • 14 Downloads

Abstract

Many substance classes have been introduced for the treatment of motor symptoms in Parkinson’s disease within the last 50 years. The most important and effective medication is still levodopa in combination with a decarboxylase inhibitor. In addition, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, amantadine (N-methyl-d-aspartate-antagonist), and less important anticholinergics are administered depending on the motor symptoms, age, and a multitude of other factors. Fortunately, within the substance classes there are various preparations, which also have different effects. In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication. In addition, important aspects are interactions and reciprocal actions. The decision as to which medication to choose must be made individually for each patient.

References

  1. Anonymous. Anticholinergic therapies in the treatment of Parkinson’s disease. Mov Disord. 2002;17:S7–12.CrossRefGoogle Scholar
  2. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet. 1998;352(9132):958.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702–5.PubMedPubMedCentralGoogle Scholar
  4. Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet. 2001;40:383–93.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Barbeau A, Sourkes TL, Murphy GF. Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra J, editor. Monoamines et système nerveux central. Paris: Masson; 1962. p. 247–62.Google Scholar
  6. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Biglan KM, Holloway RG. A review of pramipexole and its clinical utility in Parkinson’s disease. Expert Opin Pharmacother. 2002;3:197–210.PubMedCrossRefGoogle Scholar
  8. Birkmayer W, Hornykiewicz O. Der l-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr. 1961;73:787–8.PubMedGoogle Scholar
  9. Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the antiakinetic effect after l-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm. 1975;36:303–26.PubMedCrossRefGoogle Scholar
  10. Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silve P. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13:352–79.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014a;29:229–37.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014b;29:1273–80.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Brecht HM. Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W, editors. Neuro-Psycho-pharmaka, vol. 5. Wien/New York: Springer; 1992. p. 226–40.Google Scholar
  14. Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P. The Parkinson-control study: a 1-year, randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with l-dopa in Parkinson’s disease. Mov Disord. 2006;21:500–9.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Cattaneo C, Ferla RL, Bonizzoni E, Sardina M. Long-term effects of safinamide on dyskinesia in mid- to late stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5:475–81.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol. 1989;12:147–66.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphin combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet. 1979; 1(8123):954–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276(7):374–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M. Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: a cross-sectional, cohort study. Pharmacotherapy. 2015;35:681–6.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Del Dotto P, Pavese N, Cambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levodopa induced dyskinesias: an acute double-blind placebo controlled study. Mov Disord. 2001;16:515–20.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Dooley M, Markham A. Pramipexole. Drugs Aging. 1998;12:495–514.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Eggert KM, Oertel WH, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Weimar C, et al., editors. Leitlinien für Diagnostik und Therapie in der Neurologie. 5th ed. Stuttgart: Thieme-Verlag; 2012. p. 124–62.Google Scholar
  23. Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH. Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014;37:116–22.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Factor SA. Intermitent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62(Suppl 4):S12–7.PubMedCrossRefPubMedCentralGoogle Scholar
  25. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.PubMedCrossRefPubMedCentralGoogle Scholar
  26. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30:500–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Ferrara JM, Stacy M. Impulse-control disorders in Parkinson’s disease. CNS Spectr. 2008; 13:690–8.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Ferreira JJ, Rocha JF, Falcão A, Santos A, Pinto R, Nunes T, Soares-da-Silva P. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22:815–25.PubMedCrossRefPubMedCentralGoogle Scholar
  29. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–65.PubMedCrossRefPubMedCentralGoogle Scholar
  30. Finberg JPM, Lamersdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95–101.PubMedGoogle Scholar
  31. Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and positron emission tomography. Science. 1987;235:481–5.PubMedCrossRefGoogle Scholar
  32. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, Wolf AP, Pappas N, Alexoff D, Shea C. Slow recovery of human brain MAO after l-deprenyl (selegiline) withdrawal. Synapse. 1994;18:86–93.PubMedCrossRefGoogle Scholar
  33. Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018; 33(8):1248–66.PubMedCrossRefGoogle Scholar
  34. Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3): S2–41.PubMedCrossRefGoogle Scholar
  35. Gouraud A, Millaret A, Descotes J, Vial T, French Association of Regional Pharmacovigilance Centres. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol. 2011;34:104–7.PubMedCrossRefGoogle Scholar
  36. Güldenpfennig WM, Poole KH, Sommerville KW. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharamcol. 2005;28:106–10.CrossRefGoogle Scholar
  37. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010;25:2542–9.PubMedCrossRefGoogle Scholar
  38. Hauser RA, Abler V, Eyal E, Eliaz RE. Efficacy of rasagiline in early Parkinson’s disease: a meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci. 2016;126:942–6.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17: 427–42.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014;20:640–3.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol. 1997;38:59–67.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Jost WH. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf. 2014;13:447–58.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Jost WH, Brück C. Drug interactions in the treatment of Parkinson’s disease. J Neurol. 2002; 249(Suppl 3):24–9.Google Scholar
  44. Jost WH, Angersbach D, Rascol O. Clinical studies with ropinirole in Parkinson’s disease and RLS. J Neurol. 2006;253(Suppl 4):IV16–21.PubMedCrossRefPubMedCentralGoogle Scholar
  45. Jost WH, Klasser M, Reichmann H. Rasagilin im klinischen Alltag. Fortschr Neurol Psychiatr. 2008a;76:594–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. Jost WH, Kuhn K, Wangemann M. Piribedil: ein neuer, bekannter Dopaminagonist. Psychopharmakotherapie. 2008b;15:102–9.Google Scholar
  47. Jost W, Retzow A, Kuhn K. Piribedil – ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von zwei Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. Nervenheilkunde. 2010;29:571–7.CrossRefGoogle Scholar
  48. Jost WH, Friede M, Schnitker J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia. 2012;2:S17–26.CrossRefGoogle Scholar
  49. Kapp W. The history of drugs for the treatment of Parkinson’s disease. J Neural Transm Suppl. 1992;38:1–6.PubMedPubMedCentralGoogle Scholar
  50. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003; CD003735.Google Scholar
  51. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson’s disease. CNS Drugs. 2005;19:165–84.PubMedCrossRefGoogle Scholar
  52. Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ. Rotigotine transdermal system for perioperative administration. J Neural Transm. 2007;114:219–21.PubMedCrossRefGoogle Scholar
  53. Kvernmo T, Härtter S, Bürger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065–78.PubMedCrossRefGoogle Scholar
  54. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin. 2002;18:209–14.PubMedCrossRefGoogle Scholar
  55. Lees AJ. Levodopa substitution: the gold standard. Clin Neuropharmacol. 1994;17:1–6.CrossRefGoogle Scholar
  56. Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:944–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197–206.PubMedCrossRefPubMedCentralGoogle Scholar
  58. Lew MF, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007;30(5):281–6.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. Long-term efficacy of rasagiline in early Parkinson’s disease. Int J Neurosci. 2010;120:404–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Lewitt PA, Boroojerdi B, Surmann E, Poewe W. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm. 2013;120:1069–81.PubMedCrossRefPubMedCentralGoogle Scholar
  61. Linazasoro G, Grandas F, Martinez Martin P, Bravo JL. Controlled release levodopa in Parkinson’s disease: influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients. Clin Neuropharmacol. 1999;22:74–9.PubMedCrossRefPubMedCentralGoogle Scholar
  62. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol. 1990;66:317–23.PubMedCrossRefPubMedCentralGoogle Scholar
  63. Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77–85.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Mazzio E, Deiab S, Park K, Soliman KF. High throughput screening to identify natural human monoamine oxidase B inhibitors. Phytother Res. 2013;27:818–28.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Metman VL, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord. 1994;9:463–5.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Metman VL, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–6.CrossRefGoogle Scholar
  67. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias – a 1 year follow-up study. Arch Neurol. 1999;56:1383–6.PubMedCrossRefGoogle Scholar
  68. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol. 2001;24:163–9.PubMedCrossRefGoogle Scholar
  69. Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20:602–10.PubMedCrossRefGoogle Scholar
  70. Müller T, Kuhn W, Przuntek H. Efficacy of budipine and placebo in untreated patients with Parkinson’s disease. J Neural Transm. 2005;112:1015–23.PubMedCrossRefPubMedCentralGoogle Scholar
  71. Müller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm. 2013;120:761–5.PubMedCrossRefPubMedCentralGoogle Scholar
  72. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol Scand. 2001;104:343–8.PubMedCrossRefPubMedCentralGoogle Scholar
  73. Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of l-dopa. Adv Neurol. 1996;69:493–6.PubMedPubMedCentralGoogle Scholar
  74. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7:35–49.PubMedCrossRefPubMedCentralGoogle Scholar
  75. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease: relation to absorption and transport. N Engl J Med. 1984;310:483–8.PubMedCrossRefPubMedCentralGoogle Scholar
  76. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol. 1987;21:584–8.PubMedCrossRefPubMedCentralGoogle Scholar
  77. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology. 1989;39(Suppl 2):11–9.PubMedPubMedCentralGoogle Scholar
  78. Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325–37.PubMedCrossRefPubMedCentralGoogle Scholar
  79. Olanow CW, Stocchi F. Safinamide – a new therapeutic option to address motor symptoms and motor complications in mid- to late-stage Parkinson’s disease. Eur Neurol Rev. 2016; 11(Suppl 2):2–15.Google Scholar
  80. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomized, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9.PubMedCrossRefPubMedCentralGoogle Scholar
  81. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82:300–7.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson’s disease. Neurol Sci. 2001;22:75–6.PubMedCrossRefPubMedCentralGoogle Scholar
  83. Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–6.PubMedCrossRefPubMedCentralGoogle Scholar
  84. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA. 2000;284:1931–8.CrossRefGoogle Scholar
  85. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol. 2002;59:1937–43.CrossRefGoogle Scholar
  86. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60:1721–8.CrossRefGoogle Scholar
  87. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–6.CrossRefGoogle Scholar
  88. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005;62:241–8.CrossRefGoogle Scholar
  89. Perez-Lloret S, Rascol O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs. 2016;30:703–17.PubMedCrossRefGoogle Scholar
  90. Perez-Lloret S, Peralta MC, Barrantes FJ. Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother. 2016;17:2405–15.PubMedCrossRefPubMedCentralGoogle Scholar
  91. Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77:759–66.PubMedCrossRefPubMedCentralGoogle Scholar
  92. Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713–20.PubMedPubMedCentralCrossRefGoogle Scholar
  93. Rajput A, Wallkait M, Rajput AH. 18 month prospective study of amantadine for DOPA induced dyskinesias in idiopathic Parkinson’s disease. Can Neurol Sci. 1997;24:S23.Google Scholar
  94. Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–96.PubMedCrossRefPubMedCentralGoogle Scholar
  95. Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35:205–7.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Røkenes Karlsen K, Grilo M, Odin P, Chaudhuri KR. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23:1255–61.PubMedCrossRefPubMedCentralGoogle Scholar
  97. Rocha JF, Almeida L, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–75.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One. 2010;5:e15298.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Schapira AHV. The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord. 2008;23(Suppl 3):S515–20.PubMedCrossRefPubMedCentralGoogle Scholar
  100. Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061–71.PubMedCrossRefPubMedCentralGoogle Scholar
  101. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W, Pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767–74.PubMedCrossRefPubMedCentralGoogle Scholar
  102. Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Safinamide as adjunct to levodopa in Parkinson’s disease patients with motor fluctuations: A 24-week randomized, double-blind, placebo-controlled trial. JAMA Neurology. 2017;74:216–224.PubMedCrossRefPubMedCentralGoogle Scholar
  103. Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol. 2002;9:253–7.PubMedCrossRefPubMedCentralGoogle Scholar
  104. Schwab RS, England AC Jr, Poskaner DC. Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc. 1969;208:1163–70.CrossRefGoogle Scholar
  105. Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol. 1998;55:1211–6.PubMedCrossRefPubMedCentralGoogle Scholar
  106. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord. 2004;19:916–23.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Stetter H, Mayer J, Schwarz M, Wulff K. Beiträge zur Chemie der Adamantanyl-(1)-Derivate. Chem Ber. 1960;93:226–30.CrossRefGoogle Scholar
  108. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68:18–27.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335–40.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Talati R, Reinhart K, Baker W, White CM, Coleman CI. Pharmacologic treatment of advanced Parkinson’s disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009;15:500–5.PubMedCrossRefPubMedCentralGoogle Scholar
  111. Tönges L, Ceballos-Baumann A, Honig H, Storch A, Jost WH. Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie. Fortschr Neurol Psychiatr. 2017;85:516–35.PubMedCrossRefPubMedCentralGoogle Scholar
  112. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord. 2008;13:1850–9.CrossRefGoogle Scholar
  113. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–9.PubMedCrossRefPubMedCentralGoogle Scholar
  114. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76:759–77.PubMedCrossRefPubMedCentralGoogle Scholar
  115. Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease. J Clin Mov Disord. 2016;3:8.  https://doi.org/10.1186/s40734-016-0036-9.CrossRefPubMedPubMedCentralGoogle Scholar
  116. Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:27–9.PubMedCrossRefPubMedCentralGoogle Scholar
  117. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–6.PubMedCrossRefPubMedCentralGoogle Scholar
  118. Weil E. De l’apomorphine dans certain troubles nerveaux. Lyon Med. 1884;48:411–9.Google Scholar
  119. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25:1357–63.PubMedCrossRefPubMedCentralGoogle Scholar
  120. Youdim MBH, Gross A, Finberg JP. Rasagiline [N-propargyl-1R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500–6.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol. 2014;21:312–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Parkinson-Klinik OrtenauWolfachGermany

Section editors and affiliations

  • Toshiharu Nagatsu
    • 1
    • 2
  • Akira Nakashima
    • 3
  1. 1.Fujita Health University School of MedicineToyoakeJapan
  2. 2.Institute of Environmental MedicineNagoya UniversityNagoyaJapan
  3. 3.Department of Physiological ChemistryFujita Health University School of MedicineToyoake, AichiJapan

Personalised recommendations